Evidence map›Paper›PMID 36341440›Full record

ReviewFrontiers in immunology2022

Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.

Qiang Feng, Baozhen Sun, Tianyi Xue, Rong Li, Chao Lin, Yongjian Gao, Liqun Sun, Yue Zhuo, Dongxu Wang

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.Journal of experimental & clinical cancer research : CR · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Qiang FengDepartment of Hepatobiliary and Pancreas Surgery, China - Japan Union Hospital of Jilin University, Changchun, China.
Baozhen SunDepartment of Hepatobiliary and Pancreas Surgery, China - Japan Union Hospital of Jilin University, Changchun, China.
Tianyi XueLaboratory Animal Center, College of Animal Science, Jilin University, Changchun, China.
Rong LiLaboratory Animal Center, College of Animal Science, Jilin University, Changchun, China.
Chao LinSchool of grain science and technology, Jilin Business and Technology College, Changchun, China.
Yongjian GaoDepartment of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Liqun SunDepartment of Pathogenobiology, Jilin University Mycology Research Center, College of Basic Medical Sciences, Jilin University, Changchun, China.
Yue ZhuoSchool of Acupuncture-Moxi bustion and Tuina, Changchun University of Chinese Medicine, Changchun, China.
Dongxu WangLaboratory Animal Center, College of Animal Science, Jilin University, Changchun, China.
Jilin University · CNUnion Hospital · CNChangchun University of Chinese Medicine · CNJilin Business and Technology CollegeJilin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bile duct, pancreatic, and gastric cancers are deadly digestive system tumors with high malignancy and poor patient prognosis. The efficiencies of conventional surgical treatment, radiation therapy, and chemotherapy are limited. In contrast, chimeric antigen receptor (CAR) T-cell therapy represents a landmark therapeutic approach to antitumor immunity with great efficacy in treating several hematological malignancies. CAR T-cell therapy involves genetically engineering the expression of specific antibodies based on the patient's T-cell surface and amplifying these antibodies to identify and target tumor-associated antigens. CAR T-cell therapy can effectively inhibit disease progression and improve the survival of patients with bile duct, pancreatic, and gastric cancers. The effectiveness of CAR T cells in tumor therapy can be validated using xenograft models, providing a scientific testing platform. In this study, we have reviewed the progress in CAR T-cell production and its development, focusing on the current status and optimization strategies for engineered CAR T cells in the bile duct, pancreatic, and gastric cancers.

Indexed as

Immunotherapy, AdoptiveStomach NeoplasmsBileHumansPancreatic DuctsT-LymphocytesCAR T cellschimeric antigen receptorsdigestive tumorsimmunotherapyxenograft models

Identifiers

PMID36341440
PMCPMC9628995
OpenAlexW4302305195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.